C01CE02 - Milrinone |
Propably not porphyrinogenic |
PNP |
Rationale
Probably no significant CYP-dependent metabolism. Hydrophilic substance, no data pointing to CYP-affinity.
Chemical description
Bipyridine derivative lactate.
Therapeutic characteristics
Used in acute heart failure. Administered as infusion about 1 mg/kgBW/24 h.
Metabolism and pharmacokinetics
Elimination occurs mainly via the urine; about 83% of a dose is excreted as unchanged drug, about 10% as O-glucuronide. Major metabolic pathways appear to be both oxidative and conjugative (primarily glucuronidation), based on animal studies. Some CYP450-mediated metabolism can therefore not be excluded. No data pointing to CYP-interaction.
Preclinical data
None
Personal communication
None
Published experience
None
Similar drugs
© NAPOS 2024